Home › Acute Biphenotypic Leukemia › Pennsylvania › Harrisburg
Acute Biphenotypic Leukemia clinical trials in Harrisburg, PA
3 studies for Acute Biphenotypic Leukemia are looking for participants at sites in and around Harrisburg (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Penn State Children's Hospital, Hershey · 12 mi away
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Penn State Children's Hospital, Hershey · 12 mi away
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Penn State Children's Hospital, Hershey · 12 mi away
Acute Biphenotypic Leukemia trials in other cities
- Seattle, WA15 studies
- Houston, TX11 studies
- New York City, NY10 studies
- Atlanta, GA9 studies
- Durham, NC8 studies
- Memphis, TN7 studies
- Chicago, IL7 studies
- Charlotte, NC6 studies
- Baldwin Park, CA6 studies
- Dallas, TX6 studies
- Philadelphia, PA6 studies
- Aurora, CO6 studies
Other studies in Harrisburg
- Heart Failure14 studies
- Breast Cancer12 studies
- Non-Small Cell Lung Cancer12 studies
- Cardiovascular Disease11 studies
- Lung Cancer9 studies
- Acute Myeloid Leukemia8 studies
- Prostate Cancer8 studies
- Colorectal Cancer7 studies
- Head and Neck Squamous Cell Carcinoma7 studies
- Neuroblastoma6 studies
- Crohn's Disease6 studies
- High Blood Pressure6 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.